Tokyo (JCN) Jan 24, 2006 - Novartis Pharma announced on January 23 that it has obtained approval for its proprietary agent, Femara Tablet 2.5mg (letrozole), from the Ministry of Health, Labor and Welfare. The new agent, which is an aromatase inhibitor, is indicated for the treatment of postmenopausal breast cancer. In particular, the agent helps reduce the risk of recurrence and achieve a prolonged disease-free survival.
